GH Research PLC (GHRS)

Market Cap	356.39M
Revenue (ttm)	n/a
Net Income (ttm)	-41.43M
Shares Out	52.03M
EPS (ttm)	-0.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	76,444
Open	7.40
Previous Close	7.39
Day's Range	6.72 - 7.63
52-Week Range	5.08 - 14.99
Beta	0.78
Analysts	Strong Buy
Price Target	35.67 (+420.73%)
Earnings Date	Nov 14, 2024

About GHRS

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company’s lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bip...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 25, 2021
• Employees: 49
• Stock Exchange: NASDAQ
• Ticker Symbol: GHRS
• Website: https://www.ghres.com

Analyst Forecast

According to 3 analysts, the average rating for GHRS stock is "Strong Buy." The 12-month stock price forecast is $35.67, which is an increase of 420.73% from the latest price.

Price Target

$35.67

(420.73% upside)

Analyst Consensus: Strong Buy